The (1R,3R)- or (1S,3S)-enantiomer of 2,2-dichloro-3-(substituted phenyl)cyclopropane-carboxylic acid is prepared in a process involving chemical resolution of a racemic mixture of a trans-2,2-dichloro-3-(substituted phenyl)cyclopropanecarboxylic acid with an enantiomeric amine, isolation of a diastereomeric amine salt and finally treatment of the salt with an acid.

The (1R,3R)- or (1S,3S)-enantiomer of 2,2-dichloro-3-(substituted phenyl)cyclopropane-carboxylic acid is prepared in a process involving chemical resolution of a racemic mixture of a trans-2,2-dichloro-3-(substituted phenyl)cyclopropanecarboxylic acid with an enantiomeric amine, isolation of a diastereomeric amine salt and finally treatment of the salt with an acid.

Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Polymorphs of co-crystals of itanapraced and nicotinamide and pharmaceutical compositions and dosage forms containing the polymorphs are described. Methods of synthesizing the polymorphs and uses of polymorphs are also described.

Polymorphs of co-crystals of itanapraced and nicotinamide and pharmaceutical compositions and dosage forms containing the polymorphs are described. Methods of synthesizing the polymorphs and uses of polymorphs are also described.